<DOC>
	<DOCNO>NCT01166984</DOCNO>
	<brief_summary>The primary objective study establish safety profile maximum tolerate dose AB103 give single intravenous infusion repeat ( 5 day ) IV infusion healthy volunteer .</brief_summary>
	<brief_title>AB103 Peptide Antagonist Healthy Volunteers</brief_title>
	<detailed_description>AB103 develop therapeutic treat severe sepsis septic shock result bacterial infection . This Phase 1 , single center , randomize , double-blind , placebo-controlled , sequential-dose escalation study approximately 34 healthy volunteer LPS challenge cohort follow dose escalation phase .</detailed_description>
	<criteria>Be 18to40 yearsofage . Have adequate venous access . Have body mass index 20 29 kg/m2 . Have history physical examination demonstrate clinically significant contraindication participate study , judgment admit physician and/or site investigator . Have vital sign follow : resting heart rate 50 90 bpm , systolic BP 150 mm Hg diastolic BP 90 mm Hg . Have blood chemistry , hematology , coagulation , urinalysis analyte level within 10 % normal laboratory limit . If female , pregnant breastfeeding , plan become pregnant duration study , negative pregnancy test . Agree exercise adequate birth control time screen procedure 14 day investigational agent administration ( male female ) . Have ECG perform demonstrate normal sinus rhythm , normal conductivity , clinically significant arrhythmia . Be pregnant lactating . Have autoimmune disease asthma . Have febrile within 3days first infusion . Have history migraine headache , diagnose physician . Have acute chronic medical illness condition , opinion Investigator , might jeopardize safety patient , adequate evaluation study result . Be take medication treat chronic medical condition . Have participate research study receive experimental product within 30 day prior study entry . Have ongoing drug abuse/dependence ( include alcohol ) medical history . Have take , within 14 day plan dosing , prescription nonprescription medication ( include ibuprofen , aspirin , nonsteroidal antiinflammatory drug ) unless Principal Investigator/SubInvestigator , consultation Medical Monitor , provide statement justify medication take impact result study ( rare exception take prescription drug ground exclusion ) . Have donate unit blood within precede 4week period . Have allergy either sulfa penicillinbased drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>sepsis</keyword>
	<keyword>septic shock</keyword>
</DOC>